Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Inks Supply Agreement with Illumina

NEW YORK (GenomeWeb) – Transplant molecular diagnostics company CareDx today announced a supply agreement with Illumina for next-generation sequencing technologies.

Under the terms of the multiyear deal, CareDx's reference and R&D laboratories will have access to Illumina's NGS, microarray equipment, and consumables. Financial and other terms were not disclosed.

CareDx's flagship service is AlloMap Molecular Expression Testing for potential heart transplant rejection. In a statement, the company's President and CEO Peter Maag said that as CareDx expands its product pipeline from the gene expression-based AlloMap to cell-free DNA-based tests, "we believe the technology solutions from Illumina will effectively support our development and commercialization efforts."

Formerly called XDx, CareDx also recently announced the acquisition of transplant firm ImmuMetrix.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.